IMMUNOCORE HOLDINGS PLC - AMERICAN DEPOSITARY SHAR

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

10 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

06 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

02 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

23 ديسمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

17 ديسمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

11 ديسمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

03 ديسمبر 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

08 نوفمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports third quarter financial results and provides a business update

06 نوفمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 سبتمبر 2024 02:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 سبتمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Immunocore announces transition of Chief Financial Officer

29 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports second quarter financial results and provides a business update

08 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 يونيو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 يونيو 2024 06:59:59 بحسب Nasdaq GlobeNewswire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at the Jefferies Global Healthcare Conference

30 مايو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore reports first quarter financial results and provides a business update

08 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire